ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers, Speaker: Fatima Carneiro

Prevention of Colorectal Cancer, Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine, Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

http://oncologypro.esmo.org/Meeting-Resourc...al-cancer-A-review-on-the-literature-of-Iran

Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer death and incidence rates of CRC are highest in Australia, New Zealand, Europe, and North America and lowest in Africa and South-Central Asia.

Date: 28 Jun 2017
Presenter: Mehrnoush Aeinfar
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...lorectal-cancer-A-study-in-Algerian-patients

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy.

Date: 28 Jun 2017
Presenter: Said Belhadef
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer, Cancer Immunology and Immunotherapy

http://oncologypro.esmo.org/Meeting-Resourc...able-colorectal-cancer-to-anti-PD-1-blockade

Anti-PD-1 immune checkpoint inhibitors have shown encouraging results in patients with high level of microsatellite instability colorectal cancer (CRC). To date, no benefit with PD-1 blockade has been...

Date: 28 Jun 2017
Presenter: Lisa Nuttin
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...nd-therapeutic-decision-of-digestive-cancers

Digestive cancers remain predominant pathologies throughout the world, and a great concern for the scientific societies .They are always a public health problem by their frequency, and their complicated and pluridisciplinary management.

Date: 28 Jun 2017
Presenter: Iyes Rahal
Resources: Abstract
Topics: Gastrointestinal Cancers, Imaging, Diagnosis and Staging

http://oncologypro.esmo.org/Meeting-Resourc...es-expressed-under-modeled-colon-pathologies

Inflammation is the main reason or accompanying phenomenon almost of all gut disorders, and its elimination is required tor successful therapy. A significant role at all the stages of inflammation and...

Date: 28 Jun 2017
Presenter: Natalya Dziubenko
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer

http://oncologypro.esmo.org/Meeting-Resourc...pectively-when-combined-with-cytotoxic-drugs

CNP exerts a catalase activity that differs between tumour and normal cells.rnThey have been reported to enhance the antitumor activity of doxorubicin, probably related to reactive oxygen species (ROS)...

Date: 28 Jun 2017
Presenter: Jose Vazquez Villa
Resources: Abstract
Topics: Gastrointestinal Cancers, Basic Science

http://oncologypro.esmo.org/Meeting-Resourc...t-and-Memorial-Sloan-Kettering-Cancer-Center

Biomedical research is fundamental for unveiling pathologies of diseases and developing more effective means for treatment and prevention. Lack of resources and data is a factor hindering biomedical...

Date: 28 Jun 2017
Presenter: mariam kanso
Resources: Abstract
Topic: Gastrointestinal Cancers

http://oncologypro.esmo.org/Meeting-Resourc...-cancer-early-detection-status-in-Uzbekistan

In 1992 incidence rate was 0.9 per 100 thousand population. In 2015 this number increased almost 4 times (3.6 per 100 thousand). However, the detection of colorectal cancer in III and IV stages remained almost the same in past 25 years - 55.

Date: 28 Jun 2017
Presenter: Sulayman Abdujapparov
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ystems-for-mega-scale-gut-microbiome-testing

The Faecal Occult Blood Test (FOBT) is now widely used in colorectal cancer (CRC) screening. Two types of FOBT tests are most commonly used: the guaiac based FOBT test and the immunochemical FOBT (FIT).

Date: 28 Jun 2017
Presenter: Davids Fridmanis
Resources: Abstract
Topics: Gastrointestinal Cancers, Cancer Aetiology, Epidemiology, Prevention

http://oncologypro.esmo.org/Meeting-Resourc...roach-to-personalized-conservative-treatment

Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of death. One in 22 men and one in 24 women will be diagnosed with colorectal cancer in their lifetime.

Date: 28 Jun 2017
Presenter: Doniyor Pulatov
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer